| Literature DB >> 24316889 |
Susobhan Sarkar1, Axinia Döring2, Franz J Zemp3, Claudia Silva1, Xueqing Lun4, Xiuling Wang4, John Kelly1, Walter Hader1, Mark Hamilton1, Philippe Mercier1, Jeff F Dunn5, Dave Kinniburgh6, Nico van Rooijen7, Stephen Robbins4, Peter Forsyth4, Gregory Cairncross8, Samuel Weiss5, V Wee Yong1.
Abstract
Brain tumor initiating cells (BTICs) contribute to the genesis and recurrence of gliomas. We examined whether the microglia and macrophages that are abundant in gliomas alter BTIC growth. We found that microglia derived from non-glioma human subjects markedly mitigated the sphere-forming capacity of glioma patient-derived BTICs in culture by inducing the expression of genes that control cell cycle arrest and differentiation. This sphere-reducing effect was mimicked by macrophages, but not by neurons or astrocytes. Using a drug screen, we validated amphotericin B (AmpB) as an activator of monocytoid cells and found that AmpB enhanced the microglial reduction of BTIC spheres. In mice harboring intracranial mouse or patient-derived BTICs, daily systemic treatment with non-toxic doses of AmpB substantially prolonged life. Notably, microglia and monocytes cultured from glioma patients were inefficient at reducing the sphere-forming capacity of autologous BTICs, but this was rectified by AmpB. These results provide new insights into the treatment of gliomas.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24316889 DOI: 10.1038/nn.3597
Source DB: PubMed Journal: Nat Neurosci ISSN: 1097-6256 Impact factor: 24.884